Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
Matteo Lucchini, Assunta Bianco, Paola Del Giacomo, Chiara De Fino, Viviana Nociti, Massimiliano Mirabella
Topics & Concepts
OcrelizumabMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SerologyCoronavirus disease 2019 (COVID-19)VirologyMultiple sclerosis2019-20 coronavirus outbreakImmunologyInternal medicineAntibodyInfectious disease (medical specialty)DiseaseOutbreakRituximabSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19